Last reviewed · How we verify
HLX26
At a glance
| Generic name | HLX26 |
|---|---|
| Also known as | Anti-LAG-3 Monoclonal Antibody, Anti-LAG-3 monoclonal Antibody Injection |
| Sponsor | Shanghai Henlius Biotech |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients (PHASE2)
- Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC (PHASE2)
- A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma (PHASE1)
- Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HLX26 CI brief — competitive landscape report
- HLX26 updates RSS · CI watch RSS
- Shanghai Henlius Biotech portfolio CI